This includes limiting caffeine and alcohol intake and reducing workload
Tirzepatide (branded Mounjaro for diabetes, Zepbound for weight management) is a dual GIP/GLP-1 agonist given weekly
I left my reconstituted PT-141 out at room temperature overnight
Tirzepatide has improved several cardiovascular risk factors, including blood pressure, cholesterol levels, and triglycerides
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss
It is also involved in the metabolism of valine, leucine, and isoleucine